Published on 29/11/2025

KPI Sets for ATMP PPQ/CPV

Advanced Therapy Medicinal Products (ATMPs) represent a significant evolution in the field of biologics. With the complexities involved in their production and validation, it is essential to establish key performance indicators (KPIs) for Process Performance Qualification (PPQ) and continued process verification (CPV). This article serves as a comprehensive guide for pharmaceutical professionals engaged in validating ATMPs, particularly in relation to viral clearance validation, spiking studies, and aseptic controls in line with regulatory expectations from the US FDA, EMA, MHRA, and PIC/S.

Understanding the Regulatory Landscape for ATMP Validation

Validation of ATMPs is critical for ensuring patient safety and product efficacy. The regulatory bodies, including the FDA, EMA, MHRA, and PIC/S, provide stringent guidelines aimed at maintaining quality throughout the product lifecycle. The International Conference on Harmonisation (ICH) guidelines, notably ICH Q5A(R2) regarding viral safety, play a crucial role in this context.

Validation processes for ATMPs must consider the unique attributes of these products, including their complex structures and mechanisms of action. Implementing a comprehensive validation strategy is vital to fulfill regulatory expectations and drive product development efficiency.

Key elements of the regulatory framework governing ATMPs include:

• Quality by Design (QbD): Emphasis on integrating quality into the product design and development phases.
• Process Validation: FDA mandates three stages: process design, process qualification, and continued process verification.
• Viral Clearance Validation: Necessary to demonstrate the elimination of viral contaminants and to ensure patient safety.
• Aseptic Processing Controls: Compliance with Annex 1 standards on manufacture and sterile medicinal products.

Understanding these regulatory requirements is crucial for developing appropriate KPIs tailored to the specific nuances of ATMPs.

Development of KPIs for PPQ and CPV in ATMPs

The establishment of KPIs in the context of PPQ and CPV is critical to monitor the ongoing performance of the manufacturing process of ATMPs. KPIs should be designed to reflect the unique characteristics of ATMP products and link back to critical quality attributes (CQAs). Identifying relevant KPIs involves a detailed assessment of process variables that can impact product quality.

When developing KPIs, consider the following steps:

1. Define Critical Quality Attributes (CQAs)

Identifying CQAs is the first step in establishing effective KPIs. CQAs for ATMPs may include:

• Potency: The product’s biological activity that is essential for its therapeutic effect.
• Identity: Verification that the product is what it claims to be.
• Purity: The degree to which the product is free from contaminants, including residual host cell proteins and other impurities.

Developing a comprehensive understanding of CQAs helps guide prioritization when establishing KPIs.

2. Establish Process Parameters

Process parameters should correlate directly with the CQAs identified. Parameters to consider may include:

• Temperature: Influences product stability and biological activity.
• pH: Affects protein stability and solubility.
• Cell Culture Conditions: Monitor variables such as cell density and medium composition.

Mapping these parameters to specific KPIs will allow real-time monitoring and control throughout the production process.

3. Implement Measurement and Data Collection Strategies

Effective data collection is essential for continually assessing the performance of production processes. Consider implementing digital data collection systems designed to capture both routine operational data and variability:

• Automated Sensors: Utilization of sensors to collect real-time data on critical parameters continuously.
• Batch Record Review: Regular audits of batch records ensure compliance is maintained throughout production.
• Process Analytical Technology (PAT): Implementing PAT methodologies facilitates real-time monitoring of processes.

Establishing effective data collection methods enables the application of robust statistical analyses to provide insights into the manufacturing performance.

Addressing Viral Clearance Validation and Spiking Studies

Viral clearance validation remains one of the pivotal aspects of ensuring the safety of biologics, especially for ATMPs derived from live sources. The ultimate goal is to demonstrate that the manufacturing process effectively inactivates and removes potential viral contaminants to acceptable limits.

1. Designing Viral Clearance Studies

Studies should be designed using standard methodologies and involve multiple stages:

• Preparation: Isolate viral contaminants, often simulating the worst-case scenario through spiking studies that introduce known quantities of viruses into the process.
• Inactivation: Use validated methodologies to ensure effective viral inactivation during manufacturing steps.
• Removal: Evaluate filtration methodologies for their efficacy in removing viral contaminants post-inactivation.

Utilizing spiking studies, where scientific methods are employed to introduce viral strains at calculated concentrations, enables the assessment of the robustness of the viral clearance process.

2. Assessing Closed and Single-Use Systems

Closed systems and single-use technologies are commonly employed in ATMP manufacturing to enhance aseptic processing and minimize contamination risk. Validation of these systems is critical in ensuring reliability and safety:

• Closed Systems: Evaluate the integrity and performance of these systems through pressure decay tests and other scientific evaluations.
• Single-Use Systems: Evaluate leakage and ensure components are free from contaminants through rigorous quality inspections.

Incorporating these technologies into your viral clearance strategy can enhance the overall safety profile of the manufactured ATMP product.

Integrating Aseptic Controls in Line with Annex 1

The manufacture of sterile products demands stringent aseptic controls to prevent contamination. Regulatory guidance from Annex 1 of the EudraLex provides detailed frameworks for implementing these controls in an aseptic manufacturing environment.

1. Implementing Aseptic Processing Controls

To comply with the standards laid out in Annex 1, consider the following key components:

• Environmental Controls: Ensure cleanroom environments are maintained through rigorous monitoring of air quality, particulate levels, and microbial bioburden.
• Personnel Hygiene: Training staff in aseptic techniques and hygiene practices is essential to reduce the contamination risk.
• Operational Procedures: Develop and validate SOPs that describe operational interactions within the aseptic area, including material handling and personnel activities.

A proactive approach in maintaining aseptic conditions not only ensures compliance but also furthers the integrity of the manufacturing process.

2. Continuous Monitoring and Control Systems

Developing a continuous monitoring system for key aspects of aseptic conditions ensures quick detection of any deviations.

• Real-time Environmental Monitoring: Implement systems that provide continual feedback on air and surface contamination.
• Data Integrity Tools: Utilize technologies to ensure data captured for monitoring is accurate, complete, and reliable.
• Corrective Actions: Prepare predefined actions to quickly address identified failures in environmental controls.

Integrating these practices will enhance process control and ensure the integrity of the ATMP product through reliable aseptic conditions.

Conclusion: Tailoring PPQ and CPV for Effective ATMP Validation

In conclusion, developing KPIs for PPQ and CPV in the production of ATMPs necessitates a thorough understanding of the regulatory environment, an emphasis on identifying CQAs, and effective monitoring systems for process parameters. By strategically addressing viral clearance validation and aseptic processing controls as outlined in Annex 1, pharmaceutical manufacturers can ensure compliance while safeguarding the efficacy and safety of their products.

Successful validation of ATMPs will not only fulfill regulatory expectations but also enhance the trust of stakeholders, thus contributing to the overall quality and acceptance of biologics in the market.